<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01718587</url>
  </required_header>
  <id_info>
    <org_study_id>2012-10-09 TC liver cirrhosis</org_study_id>
    <nct_id>NCT01718587</nct_id>
  </id_info>
  <brief_title>Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients</brief_title>
  <official_title>Difference in Efficacy Between Umbilical Cord Mesenchyma Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General Hospital of Chinese Armed Police Forces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current treatment methods of liver cirrhosis are limited ,including antiviral
      therapy,supportive therapy and liver transplantation. Antiviral therapy and Supportive
      therapy especially the regularly intravenous infusions of plasma or albumin are combined in
      the clinical classical therapy treatment. In the other hand,umbilical cord mesenchyma stem
      cell with self and directed differentiation capacity can effectively rescue experimental
      liver failure and contribute to liver regeneration, which suggests the feasibility of stem
      cell transplantation therapy. In this study, the safety and efficacy of umbilical cord
      mesenchyma stem cell transplantation through interventional procedures and classical therapy
      in patients liver cirrhosis will be evaluated and compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will includ two research centers, the number of patients in transplantation group
      will be 30, the number of patients in classical therapy group will be 30. All the inclusion
      and exclusion criteria will be same and the data analysis will be complete by the
      epidemiological commissioner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver volume calculated by MRI</measure>
    <time_frame>baseline</time_frame>
    <description>Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in liver volume calculated by MRI at 6 months</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in liver volume calculated by MRI at 12 months</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood biochemistry</measure>
    <time_frame>baseline, 1,3,6 and 12 months after treatment or transplantation</time_frame>
    <description>alanine aminotransferase
aspartate aminotransferase
gamma-glutamyltransferase(GGT)
alkaline phosphatase
total bilirubin
direct bilirubin
The total bile acid (TBA)
albumin
the proportion of white balls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood test</measure>
    <time_frame>baseline,1,3,6 and 12 months after treatment or transplantation</time_frame>
    <description>platelet count (PLT)
mean platelet volume (MPV)
platelet distribution width (PDW)
platelet hematocrit (PCT)
alpha feto protein (AFP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver enzyme fiber spectrum</measure>
    <time_frame>baseline,1,3,6 and 12 months after treatment or transplantation</time_frame>
    <description>laminin (LN)
Ⅳ collagen detection (CIV)
hyaluronic acid (HA)
procollagen Ⅲ(PC Ⅲ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coagulation</measure>
    <time_frame>baselin,1,3,6 and 12 months after treatment or transplantation</time_frame>
    <description>prothrombin time (PT)
activated partial thromboplastin time (APTT)
fibrinogen (FIB)
thrombin time (TT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portal vein and splenic vein measure</measure>
    <time_frame>baseline,1,3,6 and 12 months after treatment or transplantation</time_frame>
    <description>1)Portal vein diameter (Dpv) 2）Portal vein maximum velocity (Vmaxpv) 3）Portal vein blood flow per minute (Qpv) 4) The splenic vein diameter (Dsv) 5) Splenic vein maximum flow velocity (Vmaxsv) 6) Splenic vein blood flow per minute (Qsv)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estrogen and progestin in blood</measure>
    <time_frame>baseline,1,3,6 and 12 months after treatment or transplantation</time_frame>
    <description>estrogen and progestin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>liver biopsy</measure>
    <time_frame>baseline,6 and 12 months after transplantation</time_frame>
    <description>The result of liver biopsy judged by the same one expert.</description>
  </other_outcome>
  <other_outcome>
    <measure>gastroscopy</measure>
    <time_frame>baseline,6 and 12 months after treatment or transplantation</time_frame>
    <description>Observe and photograph the related varicose veins.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>stem cell transplantation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiviral therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cell transplantation through interventional procedure</intervention_name>
    <description>interventional procedure once</description>
    <arm_group_label>stem cell transplantation therapy</arm_group_label>
    <other_name>UCMSC transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiviral therapy (lamivudine, other antiviral drugs)</intervention_name>
    <description>lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).</description>
    <arm_group_label>antiviral therapy</arm_group_label>
    <other_name>lamivudine or other antiviral drugs.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of liver cirrhosis;

          -  Without hepatic encephalopathy;

          -  No ascites or have easily dissipated ascites;

          -  Value of bilirubin is less than 100;

          -  Value of albumin is greater than 16 g / L;

          -  Prothrombin time is less than 21 seconds;

        Exclusion Criteria:

          -  Severe cardiovascular disease, and immunocompromised patients;

          -  Patients with localized lesions affecting graft infection;

          -  Coagulation disorders;

          -  Liver nodules more than 2cm or Liver cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihua An, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Stem Cell Transplantation, the General Hospital of Chinese People's Armed Police Force</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihua An, PhD</last_name>
    <phone>0086-10-57976845</phone>
    <email>doctoran2010@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yihua An</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2012</study_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbilical cord mesenchyma stem cell</keyword>
  <keyword>liver cirrhosis</keyword>
  <keyword>antiviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

